Difficulty: Medium
Average Score: 69%
Practice
Select the longer acting ocular beta blocker
Correct answer
D
Rationale
In this question, the correct answer is D) Levobunolol. Levobunolol is a longer-acting ocular beta blocker compared to the other options provided.
Levobunolol has a longer duration of action due to its lipophilic properties which allow it to penetrate the cornea and provide sustained intraocular pressure reduction over an extended period of time. This makes it a preferred choice for patients requiring once-daily dosing and better compliance.
Now, let's discuss why the other options are incorrect:
A) Timolol: Timolol is a well-known beta blocker used in the treatment of glaucoma and ocular hypertension, but it is not the longest-acting among the options provided.
B) Betaxolol: Betaxolol is a cardioselective beta blocker and is not known for its long duration of action in the treatment of glaucoma.
C) Cartelol: Cartelol is a non-selective beta blocker with intrinsic sympathomimetic activity, but it is not classified as a longer-acting ocular beta blocker compared to Levobunolol.
In an educational context, understanding the pharmacokinetic properties of different ocular beta blockers is crucial for healthcare professionals involved in the management of glaucoma and ocular hypertension. Choosing the appropriate medication based on factors like duration of action can significantly impact treatment outcomes and patient adherence. It is essential for students and practitioners to be familiar with the specific characteristics of each medication to make informed clinical decisions.
Levobunolol has a longer duration of action due to its lipophilic properties which allow it to penetrate the cornea and provide sustained intraocular pressure reduction over an extended period of time. This makes it a preferred choice for patients requiring once-daily dosing and better compliance.
Now, let's discuss why the other options are incorrect:
A) Timolol: Timolol is a well-known beta blocker used in the treatment of glaucoma and ocular hypertension, but it is not the longest-acting among the options provided.
B) Betaxolol: Betaxolol is a cardioselective beta blocker and is not known for its long duration of action in the treatment of glaucoma.
C) Cartelol: Cartelol is a non-selective beta blocker with intrinsic sympathomimetic activity, but it is not classified as a longer-acting ocular beta blocker compared to Levobunolol.
In an educational context, understanding the pharmacokinetic properties of different ocular beta blockers is crucial for healthcare professionals involved in the management of glaucoma and ocular hypertension. Choosing the appropriate medication based on factors like duration of action can significantly impact treatment outcomes and patient adherence. It is essential for students and practitioners to be familiar with the specific characteristics of each medication to make informed clinical decisions.